Fiche publication
Date publication
août 2019
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand
Tous les auteurs :
Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebbé C
Lien Pubmed
Résumé
Primary mucosal melanomas represent a minority of melanomas, but have a significantly worse prognosis than cutaneous melanomas. A better characterization of the molecular pathogenesis of this melanoma subtype could help us understand the risk factors associated with the development of mucosal melanomas and highlight therapeutic targets. Because the Mitogen-Activated Protein Kinase (MAPK) pathway plays such a significant role in melanoma development, we explore v-raf murine sarcoma viral oncogene homolog B ( and neuroblastoma RAS viral oncogene homolog ( mutations in mucosal melanoma and compare them to the mutation profiles in cutaneous melanoma and other tumors with and mutations. We show that in addition to being less frequent, and mutations are different in mucosal melanoma compared to cutaneous melanomas. Strikingly, the and mutation profiles in mucosal melanoma are closer to those found in cancers such as lung cancer, suggesting that mutations in mucosal melanoma could be linked to some genotoxic agents that remain to be identified. We also show that the atypical and mutations found in mucosal melanomas have particular effects on protein activities, which could be essential for the transformation of mucosal melanocytes.
Mots clés
BRAF, MAPK, NRAS, mucosal melanoma, mutations, targeted therapies
Référence
Cancers (Basel). 2019 08 8;11(8):
